Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
Date:7/22/2009

THE WOODLANDS, Texas, July 22 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2009 financial results on Tuesday, July 28, 2009 before the financial markets open. Lexicon management will hold a conference call to discuss its clinical development progress and financial results for second quarter 2009 at 11:00 a.m. Eastern Time on July 28, 2009.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international). The conference ID for all callers is 17788499. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through August 4, 2009.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's g
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
2. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
3. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
4. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
5. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
6. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
7. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
11. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in high ... PandaPLUS 2000, which is ideal for new applications for ... disruption . This compact laboratory homogenizer is the perfect ... food additives and ingredients as well as for the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The laboratory ... that has witnessed a number of technological advancements due ... regulatory requirements, growing need to integrate healthcare systems, and ... ease challenges in system integration. Key players in the ...
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2
... of Dane County's largest health systems, Gov. Jim Doyle ... to help healthcare providers convert to electronic health records. , ,But ... the east clinic of Dean Health Systems in Madison, ... address. In that speech, Doyle is expected to outline key initiatives ...
... that could lead to a local expansion, Cardinal Health ... technologies and services (PTS) segment, including the Middleton-based Gala ... billion in cash. , ,Cardinal Health, a Dublin, Ohio-based provider ... since 2002. The transaction is not expected to immediately impact ...
... in a series of articles on developing start-up companies in the ... - By now you have clarified what your intellectual property ... to form an entity. In this column, we will discuss ... find most useful at this early stage. , ,In today's landscape, ...
Cached Biology Technology:Doyle seeks $30M for e-medical record adoption 2Doyle seeks $30M for e-medical record adoption 3Gala Biotech among companies sold for $3.3 billion 2Early Stage: Step 5 - Forming the entity 2Early Stage: Step 5 - Forming the entity 3Early Stage: Step 5 - Forming the entity 4
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... This release is available in Spanish . ... and their relation to precipitation is the title of the ... the Basque Country (UPV/EHU). In fact, since systems for the detection ... possibility of estimating the precipitation produced in a storm as a ...
... Mich. --- Lakes, streams and wetlands are not isolated ... colleagues are pioneering a new field of research to ... Patricia Soranno, associate professor of fisheries and wildlife, ... to gauge land use and climate change,s impact on ...
... A person,s ability to battle viruses at the cellular ... prions misfold and cluster native proteins to cause disease, ... marks the first discovery of so-called "good" prion-like proteins ... proteins involved in innate immunity: the way the body ...
Cached Biology News:Lightning is less frequent in winter, but is much more noticeable than in summer 2Lightning is less frequent in winter, but is much more noticeable than in summer 3MSU professor launches new field of water research, nets $2.2 million NSF grant 2'Good' prion-like proteins boost immune response, UT Southwestern scientists report 2
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... reagent has been developed for use ... reduction of nonspecific background staining due ... describe blocking peroxidase with hydrogen peroxide. ... in combination with additional novel components ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Biology Products: